News Akeso and CStone secure China clearances for next-generation... Hong Kong biopharma company Akeso has secured clinical trial clearance in China for a next-generation antibody-drug conjugate (ADC) targeting B7-H3.
News Sandoz adds 10 biosimilars through $322m Henlius deal Sandoz is set to add up to 10 new biosimilar assets to its portfolio under a new collaboration deal with China’s Shanghai Henlius Biotech.
R&D GLP-1 RAs in CKM management: A Q&A with CORXEL GLP-1 RA medicine has transformed treatment of metabolic diseases such as obesity and diabetes. We spoke with China's CORXEL about theirs.
News TransThera's resistant biliary cancer drug cleared in China TransThera's Yochanra has been cleared in China as the world's first drug that can overcome resistance to FGFR inhibitors in cholangiocarcinoma.
News Takeda gets first OK for orexin narcolepsy drug, in China China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder narcolepsy.
News AstraZeneca adds another Chinese asset, from Dizal AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5bn licensing deal for Dizal Pharma's lung cancer therapy Zegfrovy.
News ESC26: Isomab safety evidence on blood vessel growth for CAD Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.